Sun begins to rise for foreign drug companies After years of frustration, western pharmaceutical groups are finally finding the going easier in the world's second-biggest market . . .Read Local companies Global firms sell direct Normalisation means rigid change, with global firms gaining acesses to local markets, and the Japanese competing in global markets - if they are big and rich enough E-initiatives Online incentives sought While e-admin could save a fortune for physicians, pharmacists and firms, too many vested interests are at stake to allow the e-revolution to get under way just yet Mergers and acquisitions Tough times ahead put pharma firms into play More competition at home and the need to expand abroad could prompt M&A activity - but local companies don't yet feel they are under pressure Case study Pursuit of the pill prescribers Nexium, AstraZeneca's ulcer replacement for Losec, gets a massive $1bn launch